Time hasn’t healed the price gouging pain that consumers felt this summer when Mylan Pharmaceutical’s hiked the price of its EpiPen 2-Pak.
The company and CEO Heather Bresch were blasted for raising the price to $600. A fiery hearing on Capitol Hill left the company reeling. Mylan agreed to pay the federal government $465 million for falsely classifying EpiPens and overcharging Medicaid.
On Friday, Mylan issued a press release about the availability of the new discounted auto-injector, used to counteract severe allergic reactions. It introduced a new website for consumers to access savings.
The statement also had Bresch’s spin on the company’s concern about broad pharmaceutical price-gouging:
Americans are rightfully concerned about rising drug prices, and now more than ever patients and families across this country are standing at the pharmacy counter struggling to pay for their medications. While it is important to understand the outdated and complex system that determines what someone pays for medicine in the U.S., hardworking families don't need an explanation, they need a solution.
Bresch says the company has taken “unprecedented and decisive action” to prevent families from facing “sticker shock for medications.” The conciliatory language also mentions that families “may be forced to make difficult choices until the pharmaceutical pricing system is reformed to address the increasing shift of costs directly to consumers.”
RELATED: Keep your cool in a crisis with these 13 tips.
The generic version features the same drug formulation as the branded product and is administered in the same way. The company is also offering a savings card for those with commercial health insurance which cuts up to $25 from out-of-pocket costs.
On social media, a host of tweets said Mylan and Bresch continue to be disingenuous and “greedy.”